Toward a standard definition and measurement of persistence with drug therapy: Examples from research on statin and antihypertensive utilization.
about
Workplace social capital and adherence to antihypertensive medication: a cohort studyLong-term use of secondary prevention medications for heart failure in Western Australia: a protocol for a population-based cohort studyLong-term use and cost-effectiveness of secondary prevention drugs for heart disease in Western Australian seniors (WAMACH): a study protocolPerformance of compliance and persistence measures in predicting clinical and economic outcomes using administrative data from German sickness funds.Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian Prescription Database.Dosage strength is associated with medication persistence with Ginkgo biloba drug products: a cohort study of ambulatory drug claims data in Germany.Off-patent generic medicines vs. off-patent brand medicines for six reference drugs: a retrospective claims data study from five local healthcare units in the Lombardy Region of Italy.A Comparison of Data Driven-based Measures of Adherence to Oral Hypoglycemic Agents in Medicaid PatientsA new taxonomy for describing and defining adherence to medicationsDevelopment and evaluation of an improved methodology for assessing adherence to evidence-based drug therapy guidelines using claims data.Antidepressant utilization after hospitalization with depression: a comparison between non-Western immigrants and Danish-born residents.Use of antithrombotic agents among U.S. stroke survivors, 2000-2006Understanding prescription adherence: pharmacy claims data from the Contraceptive CHOICE ProjectMedication adherence: a review of pharmacy education, research, practice and policy in Finland.Long-term use of antiplatelet drugs by stroke patients: a follow-up study based on prescription register data.Comparison of pharmacy-based measures of medication adherence.How to use pharmacy claims data to measure patient nonadherence? The example of oral diabetics in therapy of type 2 diabetes mellitus.Statin initiation and treatment non-adherence following a first acute myocardial infarction in patients with inflammatory rheumatic disease versus the general population.Discontinuation of anti-hypertensive drugs increases 11-year cardiovascular mortality risk in community-dwelling elderly (the Bambuí Cohort Study of Ageing)Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic reviewPatient adherence and persistence with Imatinib, Nilotinib, Dasatinib in clinical practice.Randomized, controlled trial of an intervention to enable stroke survivors throughout the Los Angeles County safety net to "stay with the guidelines".Chronic kidney disease is associated with adverse outcomes among elderly patients taking clopidogrel after hospitalization for acute coronary syndrome.Statin adherence and the risk of major coronary events in patients with diabetes: a nested case-control study.Usage, risk, and benefit of weight-loss drugs in primary care.Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort studyAdherence to antihypertensive medications: is prescribing the right pill enough?A pilot study identifying statin nonadherence with visit-to-visit variability of low-density lipoprotein cholesterolLongitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction.Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databasesAn algorithm to identify medication nonpersistence using electronic pharmacy databases.Role of Tiotropium in Reducing Exacerbations of Chronic Obstructive Pulmonary Disease When Combined With Long-Acting β2 -Agonists and Inhaled Corticosteroids: The OUTPUL StudyPersistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature.Prevalence, incidence and persistence of etanercept and adalimumab in Norway 2005-2009.Monitoring treatment adherence in hypertension.Refill adherence and self-reported adverse drug reactions and sub-therapeutic effects: a population-based study.Trends in statin therapy initiation during the period 2000-2010 in Israel.Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: Applying a coherent framework to drug utilisation studies.Use of pharmacy records to measure treatment adherence: a critical review of the literature.Buprenorphine Treatment and Patient Use of Health Services after the Affordable Care Act in an Integrated Health Care System.
P2860
Q28477035-01121B03-A34D-41B8-AA57-097C14EA3555Q28591667-916B7A64-23A6-4D76-ADF0-0D89E3F7D3F5Q28655596-B8AA1F08-71BB-41B0-BF13-ED675BC2325EQ30571895-C00F2FA4-A424-4D0D-BA8A-0E2321513596Q30647619-314A337E-9BAF-4882-B987-AEFDAC052E4FQ30683521-D6ED1F23-1A7E-4EAF-9371-93365217E36BQ30724115-12583F0B-C8B2-4AB0-BC9E-F5A7956BA363Q30947003-87D331D3-8AE7-4FAE-94CD-61F30F7EAEA9Q31054192-E27ED8AB-E21E-4E93-B759-FB13017C957AQ31170820-A22ADB12-FC94-467C-BE3F-8680774B7AC3Q33582832-0C974CD0-FF50-4A06-B6F0-BF8BD6359D5EQ33640489-3E52252D-094F-47FD-8C18-1A2EAD111C80Q33844202-497EF292-F7A4-428F-827C-55D5C5562372Q34021626-E938D5AA-3F27-4127-B8CA-0003ED65F1FAQ34265843-EC2F0A09-132B-447A-AE3E-7666D218A46FQ34301255-E5F6485D-FF73-41DC-8F8C-F78C03F0A5B0Q34344393-6BF5F877-40AF-4035-BB6F-56E10D95FB88Q34363307-921DE44B-0731-47F6-9DE7-D75E2AEDA34AQ34468039-4AA0165B-89EE-4F77-A090-0E76A951F183Q34554376-84A09CAD-B59D-4FE2-988C-EE9C621C5675Q34599540-EE0E2DDA-B90F-4493-85D2-BE4CDDA71C10Q34726959-6BAA4A03-1CF9-4AE6-BCB2-F8672468A50EQ34728842-C54725F6-BAD2-4F54-96C3-7DECA16E82A2Q34976504-A23FC90C-DE19-4B79-945F-A757F5A209B8Q35113912-1205B226-3072-40EF-8B08-70EC0A5CD2AEQ35388991-59496A92-7B0D-4E8E-B106-89C1887F24BAQ36475160-F7C04D1C-3663-466D-8934-272C52C37C2EQ36816213-B9B77232-738C-47AE-AF0E-C440A21E0AC2Q36913838-F283D7FA-BF15-4454-9D14-05326D6FC621Q37055744-D9C54E05-F438-4E33-8D22-A9BA560F686CQ37229253-A74FB6D3-D82F-4BD9-9180-F3C1F8271948Q37418094-A0C633B9-A966-400E-976D-D24AFC7DB28DQ37864717-329DD13E-5827-4228-9C6F-21F5400C2C10Q37869451-E97B2D70-59AE-47B0-A84A-ACCBB6DC4642Q38119410-A3969AF2-458B-489D-8AC1-A3E434AED404Q38152746-4310830B-76F3-4569-8735-9ABB2A21CC47Q38181893-C56ED7D7-C807-4E52-96C1-3154A5F2C197Q38655829-5D5E8C69-6148-43A3-BEF8-4D0EFB971A69Q38819475-DFA41283-D3B3-41BB-A435-3D906E8451F0Q38828787-1BA4E278-E85B-4663-AAFB-DADD232C95B0
P2860
Toward a standard definition and measurement of persistence with drug therapy: Examples from research on statin and antihypertensive utilization.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Toward a standard definition a ...... antihypertensive utilization.
@ast
Toward a standard definition a ...... antihypertensive utilization.
@en
type
label
Toward a standard definition a ...... antihypertensive utilization.
@ast
Toward a standard definition a ...... antihypertensive utilization.
@en
prefLabel
Toward a standard definition a ...... antihypertensive utilization.
@ast
Toward a standard definition a ...... antihypertensive utilization.
@en
P2093
P1476
Toward a standard definition a ...... antihypertensive utilization.
@en
P2093
Jonathan M C Lam
Patricia A Caetano
Steven G Morgan
P304
1411-24; discussion 1410
P356
10.1016/J.CLINTHERA.2006.09.021
P577
2006-09-01T00:00:00Z